• Scan

    What is Siascopy?

    MedX produces the Siascope which is a handheld siascopy medical device used in conjunction with the SIMSYS™ and MoleMate™ range of software. What is Siascopy? Spectrophotometric Intracutaneous Analysis (SIA) is a fast, non-invasive and completely safe method of pigmented skin lesions differentiation with distinct advantages over clinical and dermatoscopic diagnosis of melanoma. It is easy […]

  • medx phototherapy banner
  • molemate-banner

    MoleMate

    The FDA approved MoleMate Skin Imaging System is a significant advance in the early detection of potentially life threatening moles and lesions. Physicians have also found the hand-held device easy to learn and use, and that it rapidly provides accurate images of the pigment, blood, and collagen below the mole or lesion. Now, for the […]

Simsys and MoleMate Benefits Any Medical Practice

- Siascopy technology: See up to 2mm beneath the skin surface
- FDA & CE Mark Approved
- Low system cost & reimbursable
- Raises your practice profile
- Easily incorporates into patient workflow
- Easy to learn technology
- Quickly identifies treatable conditions resulting in fewer biopsies
- Integrates easily into all EMR systems
- Non-invasive, pain free
- Immediate results
- Clear, concise patient reports
- 90 minute training CD included
- On screen views enhance patient/MD consultation
- Fewer biopsies, no delay in results
- Helps identify/guide treatment for all mole types: Benign, SCC, BCC, Malignant Melanoma, etc.

Recent News

MedX Health Corp. Announces Approval of Debt Settlement and AGM Results

Mississauga, ON, June 25, 2014 – MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announces that at its Annual and Special Meeting of Shareholders held on June 24, 2014, all resolutions proposed to shareholders were duly passed, including the approval of the issuance of 1,742,415 common shares relating to a settlement in November, 2013 […]

MedX Health Corp. Announces First Quarter 2014 Financial Results

Mississauga, ON, May 29, 2014 – MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the three months ended March 31, 2014, which are also available on SEDAR (www.sedar.com). The Company reported a loss of $268,732, or $0.00 per share for the three months ended March 31, 2014, compared with a […]

MedX Health Corp. Announces Closing of Second Tranche of Private Placement

Mississauga, ON, May 9, 2014 – MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announces that it has closed on a second tranche of a private placement, as previously announced on January 22, 2014.  Trapeze  Capital  Corp.,  acted as  lead  agent  (the  “Agent”),  to  raise  gross proceeds of up to $2.0 million, from accredited […]

simsys2

SIMSYS-MoleMate

SIMSYS-MoleMate • MoleMate is a non-invasive, rapid, and painless melanoma screening device that has been specifically designed with and for Dermatologists, General Practitioners and skin specialists. SIMSYS is an image management system with enhanced lesion visualization and comprehensive patient image & data storage capabilities. For more information, please go to Simsys-Molemate.com or

MedX Health Headquarters

Medx Health Corp.
1495 Bonhill Road, Unit # 1
Mississauga, ON
Canada
L5T 1M2

MedX Health Corp. Phone Numbers

Toll Free: 888.363.3112 (Canada/US only) Phone: 905.670-4428 Fax: 905.670-4749